CD8A and myeloid sarcoma: Later, a humanized α4 integrin blocking antibody, natalizumab, was shown to block the transmigration of immune cells from MS patients across layers mimicking BBB in vitro and reduce the CD4/CD8 T cell ratio in CSF from MS patients [119] as well as the relapse frequency in MS patients [120].